Member
Kairu Therapeutics
Kairu Therapeutics develops non-opioid therapeutics for pain management, focusing on compounds that modulate the α2A adrenergic receptor to provide effective pain relief without sedation, addiction, or respiratory compromise. Its lead oral analgesic for neuropathic pain is advancing towards an IND filing, and the company's broader pipeline targets unmet needs in pain and neurobiology applications.
Industries
Biotech
Pharmaceutical
Healthcare
Nr. of Employees
small (1-50)
Kairu Therapeutics is currently seeking investment
Kairu Therapeutics is seeking a pre-seed investment in the range of 1m-5m
Products
Oral non-opioid analgesic for acute and neurpathic pain
First-in-class orally administered analgesic drug for moderate-to-severe pain, based on modulation of the α2A adrenergic receptor.
Oral non-opioid analgesic for acute and neurpathic pain
First-in-class orally administered analgesic drug for moderate-to-severe pain, based on modulation of the α2A adrenergic receptor.
Expertise Areas
- Non-opioid pain therapeutics
- Adrenergic receptor pharmacology
- Neuropathic pain management
- Preclinical drug development
Key Technologies
- Selective receptor signaling modulation
- b2A adrenergic receptor targeting
- Oral analgesic drug design